TearSolutions
Charlottesville, US · Founded 2015 · Delaware corporation · 10 employees on LinkedIn · 2 known investors
Find your way into TearSolutions
565 people in our graph share verified history with the TearSolutions team — schools, employers, funds. One of them is your warm intro.
Frank Rotmanunlockedknows Gordon Laurie · together at Department of Cell Biology, University of Virginia (overlapped)
knows the team · via McGill University
knows the team · via Department of Cell Biology, University of Virginia
×5knows the team · via William & Mary
×3knows the team · via National Institutes of Health
knows the team · via McMaster University
TearSolutions develops Lacripep, a topical peptide therapy derived from the Lacritin protein for the treatment of dry eye disease, including cases associated with primary Sjögren's Syndrome. The company is running clinical trials of the drug candidate for patients with moderate to severe dry eye.
Founders & leadership
TearSolutions was founded in 2015 by Gordon Laurie and Mark B. Logan.
GL
Gordon LaurieinCo-founder & Chief Scientific OfficerGordon Laurie discovered lacritin, a tear-specific protein found to be deficient in dry eye disease, and co-founded TearSolutions in 2013 to develop Lacripep, a synthetic peptide derived from lacritin for topical treatment of dry eye.
MB
Mark B. LoganinCo-founder & Director
RJ
Robert J DempseyinChair of the Board of Directors2023–2025Robert J Dempsey previously served as Group Vice President and Head of Global Ophthalmology at Shire (acquired by Takeda), where he led the divestiture of Xiidra to Novartis. He is currently CEO of OKYO Pharma, developing urcosimod for neuropathic corneal pain and inflammatory eye diseases.
AA
Anil AsraniinPresident and CEOAnil Asrani is an Executive Officer and Director at TearSolutions, a company developing Lacripep, a topical peptide therapy for dry eye disease and primary Sjögren's Syndrome. He brings market, business, and product development expertise from the medical device industry.
TG
Thomas GadekExecutive
SA
Sanjay AsraniPresident & CEO
CR
Colin RolphinCFO
Board
LM
Louis M AlpernBoard director
JR
JB
Jens BiertumpelBoard director
KD
AS
Amir ShojaeiBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$39.5M disclosed across 11 rounds · 2014–2025
▶$517KraisedNov 2025 · 12 investors · BiotechnologyRule 506(b)
▶$517KraisedNov 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James M RameyDirector
- Amir W ShojaeiDirector
- Colin M RolphExecutive Officer
- Gordon W LaurieExecutive Officer
- Robert J DempseyExecutive Officer, Director
- Mark B LoganDirector
- Anil W AsraniExecutive Officer, Director
- Jens BiertumpelDirector
- Louis M AlpernDirector
- Offering amount
- $517K
- Amount sold
- $517K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.7MraisedOct 2024 · 80 investors · BiotechnologyRule 506(b)
▶$12.7MraisedOct 2024 · 80 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jens BiertumpelDirector
- Colin M RolphExecutive Officer
- Mark B LoganDirector
- Anil AsraniExecutive Officer, Director
- Robert J DempseyExecutive Officer, Director
- Gordon W LaurieExecutive Officer
- Louis M AlpernDirector
- James RameyDirector
- Amir ShojaeiDirector
- Offering amount
- $14M
- Amount sold
- $12.7M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$390KraisedAug 2024 · 10 investors · BiotechnologyRule 506(b)
▶$390KraisedAug 2024 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Louis M AlpernDirector
- James RameyDirector
- Colin M RolphExecutive Officer
- Mark B LoganDirector
- Amir ShojaeiDirector
- Robert J DempseyExecutive Officer, Director
- Jens BiertumpelDirector
- Anil AsraniExecutive Officer, Director
- Gordon W LaurieExecutive Officer
- Offering amount
- $3M
- Amount sold
- $390K
- Minimum investment
- $25K
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.6MraisedJan 2022 · 44 investors · BiotechnologyRule 506(b)
▶$5.6MraisedJan 2022 · 44 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Anil AsraniExecutive Officer, Director
- Alexey ChernushkinDirector
- Laurie GordonExecutive Officer
- Bruce P. KupperDirector
- Michelle CarpenterExecutive Officer
- Mac ThompsonExecutive Officer
- Marc OdrichExecutive Officer
- Mark B. LoganExecutive Officer, Director
- Leonard BorrmannDirector
- Colin RolphExecutive Officer
- Jens BiertumpelDirector
- Offering amount
- $7M
- Amount sold
- $5.6M
- First sale
- Jul 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedFeb 2020 · 36 investors · BiotechnologyRule 506(b)
▶$1.5MraisedFeb 2020 · 36 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Thomas GadekExecutive Officer, Director
- Gordon LaurieExecutive Officer
- Colin RolphExecutive Officer
- Marc OdrichExecutive Officer
- Michelle CarpenterExecutive Officer
- Jens BiertumpelDirector
- John MooreExecutive Officer
- Bruce KupperDirector
- William McIlwaine Thompson, Jr.Executive Officer
- Alexey VinogradovDirector
- Mark LoganExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$1.3MraisedApr 2019 · 16 investors · BiotechnologyRule 506(b)
▶$1.3MraisedApr 2019 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John MooreExecutive Officer
- Bruce KupperDirector
- Colin RolphExecutive Officer
- Gordon LaurieExecutive Officer
- Thomas GadekExecutive Officer, Director
- William McIlwaine Thompson, Jr.Executive Officer
- Marc OdrichExecutive Officer
- Mark LoganExecutive Officer, Director
- Jens BiertumpelDirector
- Alexey VinogradovDirector
- Michelle CarpenterExecutive Officer
- Offering amount
- $1.3M
- Amount sold
- $1.3M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$5.1MraisedApr 2019 · 22 investors · BiotechnologyRule 506(b)
▶$5.1MraisedApr 2019 · 22 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jens BiertumpelDirector
- Alexey VinogradovDirector
- William McIlwaine Thompson, Jr.Executive Officer
- Bruce KupperDirector
- John MooreExecutive Officer
- Mark LoganExecutive Officer, Director
- Michelle CarpenterExecutive Officer
- Marc OdrichExecutive Officer
- Colin RolphExecutive Officer
- Thomas GadekExecutive Officer, Director
- Gordon LaurieExecutive Officer
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$8.1MraisedDec 2017 · 24 investors · BiotechnologyRule 506(b)
▶$8.1MraisedDec 2017 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- W. McIlwaine Thompson, Jr.Executive Officer
- Mark LoganDirector
- Colin RolphExecutive Officer
- Alexey VinogradovDirector
- Tom GadekExecutive Officer, Director
- Bruce KupperDirector
- Offering amount
- $9.2M
- Amount sold
- $8.1M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Alcon15 shared keywordsAlcon develops eye care products and medical technologies, including the Valeda Photobiomodulation (PBM) system for retina treatment, for eye care professionals such as retina specialists.
1Mg13 shared keywordsThis is a product listing page on an online pharmacy for Tugain Twins 5 Solution, a topical minoxidil-based medicine sold to treat hair loss and promote hair regrowth. The page provides usage instructions, benefits, side effects, and purchase/return details rather than describing a company.
Walgreens11 shared keywordsWalgreens operates a pharmacy and retail health and wellness business, offering prescription services, over-the-counter medications, health products, and photo services to consumers.
Companies competing with TearSolutions for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does TearSolutions do?
- TearSolutions develops Lacripep, a topical peptide therapy derived from the Lacritin protein for the treatment of dry eye disease, including cases associated with primary Sjögren's Syndrome. The company is running clinical trials of the drug candidate for patients with moderate to severe dry eye.
- Who founded TearSolutions?
- TearSolutions was founded by Gordon Laurie, Mark B. Logan in 2015.
- Who are TearSolutions's investors?
- TearSolutions's investors include LaunchCapital, VTC Ventures.
- How much funding has TearSolutions raised?
- TearSolutions has disclosed $39.5M raised across 11 rounds.
- Where is TearSolutions headquartered?
- TearSolutions is headquartered in Charlottesville, US.